CAS: 1127442-82-3; Rel-4-((3Ar,4S,7R,7As)-1,3-Dioxo-1,3,3A,4,7,7A-Hexahydro-2H-4,7-Methanoisoindol-2-yl)-N-(Quinolin-8-yl)Benzamide

专利信息

专利号:US-2022298019-A1
优先权日:2019-06-06
标题 :Direct Synthesis of Aluminosilicate Zeolitic Materials of the IWR Framework Structure Type and their Use in Catalysis
发明人：PARVULESCU ANDREI-NICOLAE; XIAO FENG-SHOU; MENG XIANGJU; WU QINMING; MUELLER ULRICH; YOKOI TOSHIYUKI; ZHANG WEIPING; KOLB UTE; MARLER BERND; DE VOS DIRK; HONG XIN
权利人:BASF SE
摘要:The present invention relates to a zeolitic material having the IWR type framework structure, wherein the zeolitic material comprises YO 2 and X 2 O 3 in its framework structure, wherein Y is a tetravalent element and X is a trivalent element, and wherein the framework structure of the zeolitic material comprises less than 5 weight-% weight-% of Ge calculated as GeO 2 and based on 100 weight-% weight-% of YO 2 contained in the framework structure, and less than 5 weight-% weight-% of B calculated as B 2 O 3 and based on 100 weight-% weight-% of X 2 O 3 contained in the framework structure. Further, the present invention relates to a process for preparing a zeo-litic material having the IWR type framework structure, wherein the zeolitic material comprises YO 2 and X 2 O 3 in its framework structure, wherein Y is a tetravalent element and X is a trivalent element.

专利号:CN-113966251-A
优先权日:2019-06-06
标题:Direct synthesis of aluminosilicate zeolitic materials of the IWR framework structure type and their use in catalysis

专利号:EP-3980178-A1
优先权日:2019-06-06
标题 :Direct synthesis of aluminosilicate zeolitic materials of the iwr framework structure type and their use in catalysis

专利号:WO-2022191130-A1
优先权日:2021-03-08
标 题:Method for proliferating cardiomyocytes, method for producing cardiomyocytes, and cardiomyocyte proliferating agent
发明人：YAMASHITA JUN; YOSHIOKA MIKI
权利人:UNIV KYOTO
摘要:Provided are a method for proliferating cardiomyocytes, a method for producing cardiomyocytes, and a cardiomyocyte proliferating agent capable of contributing to cardiac regenerative medicine, that make it possible to induce proliferation of human cardiomyocytes by a drug. The method for proliferating cardiomyocytes, method for producing cardiomyocytes, and cardiomyocyte proliferating agent, including a step for culturing cardiomyocytes in the presence of one or more compounds selected from the group consisting of ALK inhibitors, cytochrome P450 omega hydroxylase inhibitors, and fatty acid synthesis inhibitors